Thymoma clinical trials
The registry lists 125 studies for Thymoma across more than 10 countries. 35 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-18.
Status
- Completed
- 47
- Recruiting
- 26
- Status unknown
- 13
- Active, not recruiting
- 12
- Terminated
- 12
- Not yet recruiting
- 8
Phase
- Phase 2
- 64
- Phase 1
- 17
- Phase 3
- 4
- Phase 4
- 2
- Early Phase 1
- 1
Where
- United States
- 54
- China
- 36
- Italy
- 10
- France
- 6
- Netherlands
- 4
- Taiwan
- 4
Who runs them
National Cancer Institute (NCI) (14) · Fudan University (4) · Georgetown University (3) · M.D. Anderson Cancer Center (3) · Shanghai Zhongshan Hospital (3) · Shanghai Pulmonary Hospital, Shanghai, China (3) · Patrick Joseph Loehrer Sr. (2) · Novartis Pharmaceuticals (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 125 — search for more.
- HEARTS Trial for Thoracic CancersRecruitingNCT07132918Phase 21 country
- A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial TumorsRecruitingNCT06248515Phase 21 country
- Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaRecruitingNCT019505721 country
- PT-112 in Subjects With Thymoma and Thymic CarcinomaRecruitingNCT05104736Phase 21 country
- Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaRecruitingNCT06885697Phase 11 country
- Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic CarcinomaRecruitingNCT07324629Phase 21 country
- A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic CarcinomasNot yet recruitingNCT07750353Phase 21 country
- Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic CancerRecruitingNCT03295227Phase 11 country
- Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial TumorsNot yet recruitingNCT07693855Not applicable1 country
- Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic CarcinomaRecruitingNCT07598955Phase 1/21 country
- Neoadjuvant Treatment For Locally Advanced Thymic CancerRecruitingNCT06019468Phase 21 country
- Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia GravisNot yet recruitingNCT075715251 country
- Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)RecruitingNCT06402708Phase 31 country
- Adjuvant Radiotherapy for Stage II/III Thymoma After Complete ResectionRecruitingNCT02633553Not applicable1 country
- Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic CarcinomaNot yet recruitingNCT07479628Phase 2
- 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial TumorsNot yet recruitingNCT07463313Phase 2/31 country
- Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural MetastasisNot yet recruitingNCT073280741 country
- Molecular Analysis of Thoracic MalignanciesEnrolling by invitationNCT013857221 country
- Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic CarcinomaRecruitingNCT06838910Phase 21 country
- Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial TumorsRecruitingNCT06186726Phase 21 country
- Molecular Analysis and Treatment Options of Thymic MalignanciesRecruitingNCT056679481 country
- Neoadjuvant Radiotherapy for Locally Advanced Unresectable ThymomaRecruitingNCT06924619Phase 21 country
- Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable ThymomaRecruitingNCT06730308Phase 21 country
- Hypofractionated Radiotherapy for Thymic Epithelial TumorsRecruitingNCT06692062Not applicable1 country
- A Study of KC1036 in Patients with Advanced Thymic TumorsRecruitingNCT05683886Phase 21 country
- Myasthenia Gravis Foundation of America Global MG Patient RegistryRecruitingNCT066177411 country
- Predictors and Prognostic Factors of Myasthenia Gravis OutcomeRecruitingNCT052146121 country
- Artificial Intelligence Prediction Tool in Thymic Epithelial TumorsRecruitingNCT063019451 country
- Robot-assisted vs VATS for ThymomaRecruitingNCT06029621Not applicable1 country
- Perioperative Efgartigimod for Thymoma and Myasthenia GravisNot yet recruitingNCT06221501Phase 2
- First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)RecruitingNCT05832827Phase 21 country
- Application of 68Ga-Pentixafor PET/CT for ThymomaRecruitingNCT06086327Early Phase 11 country
- Folinic Acid for Prevention of Pemetrexed-induced ToxicityRecruitingNCT06010277Phase 41 country
- The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.Not yet recruitingNCT05816694Phase 21 country
- Study on Proton Radiotherapy of Thymic MalignanciesRecruitingNCT04822077Not applicable1 country
- An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent ThymomaActive, not recruitingNCT03968315Not applicable1 country
- Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After ChemotherapyCompletedNCT07824505Phase 21 country
- SP Thoracic IDE StudyActive, not recruitingNCT05150210Not applicable1 country
- CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid TumorsSuspendedNCT07181720Phase 11 country
- Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic CarcinomaActive, not recruitingNCT04417660Phase 21 country
- A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyActive, not recruitingNCT03076554Phase 21 country
- Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic CancerActive, not recruitingNCT03463460Phase 21 country
- Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic CarcinomaActive, not recruitingNCT01025089Phase 21 country
- IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersActive, not recruitingNCT06790706Phase 21 country
- Depressive Tendency and Counseling Outcomes in Thymoma-Associated MGCompletedNCT07649187Not applicable1 country
- Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)Active, not recruitingNCT03134118Phase 26 countries
- Adjuvant Treatment for Incomplete Resection Thymoma or Thymic CarcinomaWithdrawnNCT02633514Phase 31 country
- 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive TumoursCompletedNCT04375267Phase 11 country
- Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)CompletedNCT054614301 country
- Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIentsCompletedNCT04710628Phase 23 countries